BACKGROUND: Lymphedema is an adverse effect of breast cancer surgery. Aqua lymphatic therapy (ALT) is a novel treatment for limb volume reduction. OBJECTIVE: The aim of this study was to examine whether ALT is a safe method and whether there are differences in adherence, limb volume, and quality of life between women who perform only self-management treatment and women who participate as well in ALT. DESIGN: Design of the study was single-blind randomized clinical trial. SETTING: The setting was in a hydrotherapy pool, 1.2 m depth, and a temperature of 32-33 degrees capital ES, Cyrillic. PATIENTS: Forty-eight women (56 +/- 10 years), with a 12.8% lymphedema relative volume, participated in the study. INTERVENTION: The control group was instructed to perform the self-management treatment. The study group joined a weekly session of ALT for 3 months in addition to the self-management therapy. MEASUREMENTS: Adherence was assessed by a self-reported diary, limb volume by a water displacement device, quality of life by the Upper Limb Lymphedema Questionnaire (ULL27), prior to, and after the intervention period. RESULTS: There was no episode of arm infection or aggravation in limb volume during the study period. ALT had a positive, statistically and clinically significant immediate effect on limb volume but no long-term effect was noted. The adherence rate to ALT was significantly higher than the adherence to self-management therapy. QOL improved in the study group. CONCLUSION:ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema. A significant immediate and insignificant long-term effect on limb volume was noted.
RCT Entities:
BACKGROUND:Lymphedema is an adverse effect of breast cancer surgery. Aqua lymphatic therapy (ALT) is a novel treatment for limb volume reduction. OBJECTIVE: The aim of this study was to examine whether ALT is a safe method and whether there are differences in adherence, limb volume, and quality of life between women who perform only self-management treatment and women who participate as well in ALT. DESIGN: Design of the study was single-blind randomized clinical trial. SETTING: The setting was in a hydrotherapy pool, 1.2 m depth, and a temperature of 32-33 degrees capital ES, Cyrillic. PATIENTS: Forty-eight women (56 +/- 10 years), with a 12.8% lymphedema relative volume, participated in the study. INTERVENTION: The control group was instructed to perform the self-management treatment. The study group joined a weekly session of ALT for 3 months in addition to the self-management therapy. MEASUREMENTS: Adherence was assessed by a self-reported diary, limb volume by a water displacement device, quality of life by the Upper Limb Lymphedema Questionnaire (ULL27), prior to, and after the intervention period. RESULTS: There was no episode of arm infection or aggravation in limb volume during the study period. ALT had a positive, statistically and clinically significant immediate effect on limb volume but no long-term effect was noted. The adherence rate to ALT was significantly higher than the adherence to self-management therapy. QOL improved in the study group. CONCLUSION: ALT was found to be a safe method, with high adherence, in treating women who suffer from mild to moderate lymphedema. A significant immediate and insignificant long-term effect on limb volume was noted.
Authors: Atilla Soran; Gina D'Angelo; Mirsada Begovic; Figen Ardic; Ali Harlak; H Samuel Wieand; Victor G Vogel; Ronald R Johnson Journal: Breast J Date: 2006 Nov-Dec Impact factor: 2.431
Authors: Carolina Fernández-Lao; Irene Cantarero-Villanueva; Angelica Ariza-Garcia; Carol Courtney; César Fernández-de-las-Peñas; Manuel Arroyo-Morales Journal: Support Care Cancer Date: 2012-08-04 Impact factor: 3.603
Authors: Annette Loudon; Tony Barnett; Neil Piller; Maarten A Immink; Denis Visentin; Andrew D Williams Journal: BMC Complement Altern Med Date: 2012-05-28 Impact factor: 3.659
Authors: Electra D Paskett; Jennifer Le-Rademacher; Jill M Oliveri; Heshan Liu; Drew K Seisler; Jeffrey A Sloan; Jane M Armer; Michelle J Naughton; Karen Hock; Michael Schwartz; Gary Unzeitig; Marianne Melnik; Lisa D Yee; Gini F Fleming; John R Taylor; Charles Loprinzi Journal: Cancer Date: 2020-10-20 Impact factor: 6.860